

Research Report

CIPLA LTD



Prepared By-

ABHISHEK SHELAR
EQUITY RESEARCH ANALYST

Company Overview

Cipla Limited, founded in 1935 by Dr. K.A. Hamied as Chemical Industrial & Pharmaceutical Laboratories Ltd, is a leading Indian multinational pharmaceutical company headquartered in Mumbai. Ranked as the third-largest pharma company in India, it specializes in affordable, high-quality, complex generic medicines, particularly in respiratory, anti-retroviral, and cardiovascular segments. With over 1,500 products across 50+ dosage forms, Cipla operates 46 manufacturing sites in 74+ markets, driven by its ethos of "Caring for Life".

Key Business segments

Overall, Cipla Limited operates diversified pharmaceutical segments across global and domestic markets.

- India Formulations: ~41%
- North America: ~21%
- South Africa & Emerging Markets: ~16%
- APIs: ~9%
- Global Access & Others: ~13%

Synopsis of Financials

Cipla Limited (December 2025 Quarter – Q3 FY26)

1. Revenue: ₹7,074 crore, almost flat YoY growth.
2. Net Profit: ₹675 crore, decline of about 57% YoY.
3. EBITDA: ₹1,255 crore with EBITDA margin around 17.7%.

Revenue remained stable around ₹7,074 crore, while net profit declined due to higher expenses and margin pressure during the quarter.

Source: Company Annual Report


Stock data (as 12th March 2026)

Nifty Price	: 23,639.00
52 week High (in Rs.)	: 1,673.00
52 week Low (in Rs.)	: 1,281.70
Market Cap. (in Crore)	: 1,07,257.12
NSE Code	: INE059A01026

Stock data




Shareholding Pattern (Dec 2025)



Financial Summary

Particulars	Mar 2023	Mar 2024	Mar 2025
Sales -	22,753	25,774	27,548
Sales Growth	4.55%	13.28%	6.88%
Expenses +	17,726	19,483	20,420
Operating Profit	5,027	6,291	7,128
OPM %	22%	24%	26%
Tax %	30%	27%	22%
Net Profit +	2,833	4,154	5,269
EPS in Rs	34.71	51.05	65.28



Quarterly Results

Particular	Dec 2024	Mar 2025	Jun 2025	Sep-25	Dec 2025
Sales -	7,073	6,730	6,957	7,589	7,074
YOY Sales Growth %	7.10%	9.19%	3.94%	7.64%	0.02%
Expenses +	5,084	5,192	5,179	5,695	5,819
Operating Profit	1,989	1,538	1,778	1,895	1,255
OPM %	28%	23%	26%	25%	18%
Other Income +	222	289	259	269	-70
Interest	15	14	14	13	14
Depreciation	280	309	253	297	278
Profit before tax	1,916	1,504	1,770	1,854	893
Tax %	17%	19%	27%	27%	24%
Net Profit +	1,575	1,214	1,292	1,353	674
EPS in Rs	19.45	15.13	16.06	16.73	8.37

Source: Screener

Yearly Results

Particulars	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	161	161	161	161	162
Reserves	18,165	20,680	23,246	26,545	31,032
Borrowings +	2,014	1,056	803	559	438
Other Liabilities +	4,514	4,960	5,089	5,267	5,702
Total Liabilities	24,855	26,857	29,300	32,533	37,334
Fixed Assets +	9,516	9,683	9,160	9,607	10,006
CWIP	969	766	1,093	1,153	1,566
Investments	2,710	2,551	3,662	5,449	7,933
Other Assets +	11,661	13,857	15,384	16,323	17,828
Total Assets	24,855	26,857	29,300	32,533	37,334

Peer Comparison

Peer Stock Performance (5Y) Indexed




Source: Trading View

Peer Financial Performance

Name	CMP Rs.	P/E	Mar Cap Rs.Cr.	Div Yld %	NP Qtr Rs.Cr.	Qtr Profit Var %	Sales Qtr Rs.Cr.	Qtr Sales Var %	ROCE %
Sun Pharma.Inds.	1825.3	36.06	437951	0.89	3381.17	18.73	15520.5	13.49	20.21
Divi's Lab.	6289.95	65.97	166978	0.47	583	8.2	2604	12.29	20.44
Torrent Pharma.	4439.5	65.22	150253	0.72	635	27.63	3303	17.59	27.05
Dr Reddy's Labs	1320	19.77	110173	0.6	1189.6	-14.42	8753.4	4.44	22.69
<u>Cipla</u>	1325.25	22.47	107051	0.98	674.25	-43.7	7074.48	0.02	22.72

Source: Screener

Synopsis Quarter Results



Cipla Limited reported a strong financial performance in its latest quarterly results, reflecting steady growth in revenue and profitability supported by strong demand across key markets such as India, the United States, and Africa. In the fourth quarter of FY2025, the company recorded consolidated revenue from operations of approximately ₹6,730 crore, representing a growth of about 9% compared with ₹6,163 crore in the corresponding quarter of the previous financial year. The growth in revenue was mainly driven by improved performance in the domestic formulations segment and stable demand in international markets.

- **Revenue Growth:** In the latest quarter (Q4 FY2025), Cipla reported revenue of around ₹6,730 crore, showing nearly 9% year-on-year growth, mainly supported by strong sales in the India formulations segment and steady demand in key global markets such as the US and Africa.
- **Profitability Improvement:** The company posted a net profit of about ₹1,222 crore, representing roughly 30% growth compared with the same quarter last year. The increase in profit reflects improved operational efficiency, better product mix, and strong performance in respiratory and chronic therapy segments.
- **Operational Performance:** Cipla recorded EBITDA of about ₹1,537 crore with margins near 22–23%, indicating stable cost management and strong operating performance. Earnings per share also improved, reflecting higher returns for shareholders.

The quarter, the company reported a consolidated net profit of ₹1,222 crore, reflecting a year-on-year increase of around 30% compared with ₹939 crore in Q4 FY2024. The rise in profitability indicates stronger operational efficiency and better product mix across therapeutic segments. Earnings before interest, tax, depreciation, and amortization (EBITDA) increased to around ₹1,537 crore, while the EBITDA margin improved to about 22.8%, highlighting enhanced operating performance and cost management during the period.

Final Outlook



CIPLA: HOLD ₹1325.00

The final outlook for Cipla Limited in an equity research report reflects a positive medium-to-long-term growth trajectory supported by consistent financial performance, strong operational efficiency, and a diversified global presence across key pharmaceutical markets. Based on the company's recent annual and quarterly results, Cipla has demonstrated stable revenue growth and improving profitability, indicating a resilient business model in the competitive pharmaceutical industry.

During FY2025, the company reported consolidated revenue of approximately ₹27,548 crore, representing around 7–8% year-on-year growth compared with ₹25,774 crore in FY2024. Net profit for the year increased significantly to about ₹5,273 crore, reflecting nearly 28% growth over the previous fiscal year. This improvement in profitability was driven by strong performance across major markets including India, the United States, South Africa, and Europe, along with a better product mix and operational efficiencies. The company also maintained strong profitability margins, with EBITDA margins close to 25–26%, indicating effective cost management and improved operating leverage.

The financial performance and strategic positioning of Cipla indicate a stable and fundamentally strong company with consistent earnings growth and solid market presence. The company's strong balance sheet, diversified geographic revenue streams, expanding product pipeline, and improving profitability provide a supportive outlook for sustained growth. Based on these factors, the overall investment outlook for Cipla remains positive, with the company expected to deliver steady revenue expansion, margin stability, and long-term shareholder value creation.

Disclaimer: The information provided on this blog is for general informational purposes only and is not intended as financial advice. While we aim to provide accurate information, please conduct your own research before making any investment decisions. This content is for informational purposes only and should not be construed as financial advice. Always consult with a financial advisor before investing.

This blog may contain links to external websites for your convenience. We do not endorse the content or views expressed in these external sites and are not responsible for their accuracy or reliability.

By using this blog, you acknowledge that you have read and understood this disclaimer and agree to its terms.